黄连素治疗精神分裂症患者代谢综合征的临床研究  

Clinical study of berberine in the treatment of metabolic syndrome in patients with schizophrenia

作　　者：张莉[1] 尹建兵[1] 瞿颖莹 杨忠[1] 尤晨[1] ZHANG Li;YIN Jianbing;QU Yingying;YANG Zhong;YOU Chen(Department of Psychiatry,the Third People′s Hospital of Changshu,Jiangsu Province,Changshu 215500)

机构地区：[1]江苏省常熟市第三人民医院精神科,常熟215500

出　　处：《南通大学学报（医学版）》2023年第6期509-512,共4页Journal of Nantong University(Medical sciences)

基　　金：常熟市卫健委资助性重点项目(CSWS201616)。

摘　　要：目的:探讨黄连素治疗精神分裂症患者代谢综合征的临床效果及安全性。方法:将98例精神分裂症代谢综合征患者随机分为3组,在原抗精神病药物基础上分别联用黄连素(黄连素组)、二甲双胍(二甲双胍组)和安慰剂(对照组)。分别在基线期和治疗第4、8、12周末测量身高和体质量,计算BMI,同时测量腰围及血压,检测空腹血糖(fasting plasma glucose,FPG)、餐后2 h血糖(two-hour postprandial blood glucose,2hPBG)、总胆固醇(total cholesterol,TC)、三酰甘油(triglyceride,TG)、高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C),并采用阳性及阴性症状量表(positive and negative symptom scales,PANSS)评估精神症状,副反应量表(treatment emergent symptom scale,TESS)评估不良反应。结果:治疗第12周末黄连素组及二甲双胍组的体质量、BMI、腰围、FPG、2hPBG及TG分别较对照组下降(P<0.05),但两组间比较差异无统计学意义(P>0.05)。黄连素组不良反应发生率低于二甲双胍组(P<0.05)。结论:黄连素可改善精神分裂症患者代谢综合征,疗效与二甲双胍相当,安全性好。Objective:To investigate the clinical effect and safety of berberine in the treatment of schizophrenia with metabolic syndrome.Methods:98 schizophrenic patients with metabolic syndrome were randomly divided into three groups,which were treated with berberine(berberine group),metformin(metformin group)and placebo(control group)respectively.The height and body mass of the patients were measured at baseline and at the end of the 4th,8th and 12th week,respectively.BMI was calculated,waist circumference and blood pressure were also measured.Fasting blood glucose(FPG),two-hour postprandial blood glucose(2hPBG),total cholesterol(TC),triglyceride(TG),high density lipoprotein cholesterol(HDL-C)and low density lipoprotein cholesterol(LDL-C)were measured,and the positive and negative symptom scale(PANSS)was used to assess psychiatric symptoms.Treatment emergent symptom scale(TESS)assesses adverse reactions.Results:At the end of the 12th week,body mass,BMI,waist circumference,FPG,2hPBG and TG in berberine group and metformin group were decreased compared with the control group(P<0.05),and there was no statistical significance between the two groups(P>0.05).The incidence of adverse reactions in berberine group was lower than that in metformin group(P<0.05).Conclusion:Berberine can improve metabolic syndrome in patients with schizophrenia,the efficacy is comparable to metformin,and the safety is better.

关 键 词：精神分裂症 代谢综合征 黄连素 二甲双胍 

分 类 号：R749.3[医药卫生—神经病学与精神病学]